Biotech innovator develops new therapies based on cells manufactured from

bone marrow; SV Life Sciences and Novo A/S provide funding round

SALT LAKE CITY and HAMBURG, Germany, July 2 /PRNewswire/ -- AlloCure
Inc., a biotechnology company at the forefront of innovative cell therapies
for the treatment of acute kidney injury, today announced the closing of a
$14.5MM Series A financing. The round was led by SV Life Sciences with Novo
A/S joining the syndicate.

"This financing represents a significant step forward in developing the
first cell therapy to effectively treat patients who are suffering from
acute kidney injury," said John Wirthlin President and CEO. "SV Life
Sciences and Novo Ventures bring tremendous depth, experience and clout to
our efforts. We look forward to working closely with our investors to
successfully commercialize this unique and proprietary technology."

Despite major advances over the past 30 years, acute kidney injury
remains treatment resistant and presents a growing critical problem for a
significant number of patients around the world.

"AlloCure has not only established itself as a leader in developing
cell therapies to treat kidney patients," said Lutz Giebel, Managing
Partner of SV Life Sciences. "They have also built an attractive and sound
business model addressing this growing and unmet medical need."

The investment is key to furthering the company's promising progress in
developing these groundbreaking treatments and entering clinical trials.
The company hopes to offer acute kidney injury patients a safe and
effective treatment option for this life threatening disease in the not too
distant future.

"The AlloCure team has developed an impressive scientific foundation
which has enabled it to obtain all the regulatory approvals necessary to
begin its Phase I Clinical Trial," said Thomas Dyrberg, Senior Partner at
Novo. "We anticipate that substantial clinical progress will be made over
the next few years."

The company will use the investment to fund the progression of its
acute kidney disease therapy through Phase II Clinical Trials over the next
three years. Funds will also be used to develop a robust pipeline targeting
other large medical markets where its cell therapy technology can address
chronic unmet needs.

About AlloCure

AlloCure is poised to become the first company to commercialize
effective cell therapies to treat various kidney diseases, organ
transplants, multi-organ injury and a number of other difficult to treat
diseases. AlloCure has developed a proprietary process to manufacture cells
derived from bone marrow which can be used in an allogeneic (does not
require tissue matching of donor and recipient) or off-the-shelf setting.
AlloCure's technology has multiple therapeutic applications which have the
potential to effectively address many large medical markets.
http://www.allocure.com

About SV Life Sciences

SV Life Sciences is a venture capital fund providing financing to
businesses at all stages of development across the human life sciences
sector, including biotechnology, pharmaceuticals, medical devices and
instruments, and healthcare information technology and services. SV Life
Sciences currently manages or advises five funds with capital commitments
of approximately $1.6 billion. http://www.svlifesciences.com

About Novo A/B

Novo A/S is the holding company of the Novo Group, and is wholly owned
by the Novo Nordisk Foundation. Novo A/S was established in 1999 to manage
the assets of the Foundation and actively make investments on behalf of the
Foundation. The Novo Ventures team consists of six Partners in Copenhagen,
one in London and two in San Francisco. With an evergreen structure, Novo
A/S annually invests approximately $100 million in venture capital into
private life sciences companies, and thus acts at a pace comparable to a
traditional $350-400 million fund. In total Novo A/S has more than $8
billion under management, which includes significant shareholdings in the
independently operating and publicly listed companies Novo Nordisk A/S and
Novozymes A/S. http://www.novo.dk

(Date:10/10/2017)... ... 2017 , ... The Pittcon Program Committee is pleased to ... who have made outstanding contributions to analytical chemistry and applied spectroscopy. Each award ... conference and exposition for laboratory science, which will be held February 26-March 1, ...

(Date:4/5/2017)... April 4, 2017 KEY FINDINGS ... expand at a CAGR of 25.76% during the forecast ... the primary factor for the growth of the stem ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem cell ... application, and geography. The stem cell market of the ...

(Date:3/30/2017)... KONG , March 30, 2017 The ... a system for three-dimensional (3D) fingerprint identification by adopting ground breaking ... into a new realm of speed and accuracy for use in ... at an affordable cost. ... ...